Regel Therapeutics details its proprietary T3 platform and development pipeline on its newly launched website, expands its Board of Directors and announces its Scientific Advisory Board.

/PRNewswire/ -- Regel Therapeutics, a next generation gene therapy company utilizing proprietary technology to develop clinical products modulating gene...

Related Keywords

Berkeley ,California ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,San Francisco ,Wendy Chung ,Orrin Devinsky ,Steve Ruchefsky ,Andrew Schiermeier ,Nadav Ahituv ,Kevin Bender ,Gord Fishell ,University Of California ,Broad Institute ,Department Of Neurology ,Harvard Medical School ,Epilepsy Center ,Therapeutic Technology ,Institute Member Of The Broad ,Regel Co ,Institute For Human Genetics ,Therapeutic Sciences ,Regel Therapeutics Inc ,Clinical Genetics At Columbia University ,Scientific Advisory Board ,Regel Co Founder Orrin Devinsky ,Scientific Advisory ,Targeted Therapeutic Technology ,Cougar Biotechnology ,Regel President ,Avencell Therapeutics ,Founder Orrin Devinsky ,Kennedy Family Professor ,Clinical Genetics ,Columbia University ,Human Genetics ,Institute Member ,Associate Professor ,Computer Amp Electronics ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Personnel Announcements ,New Products Amp Services ,